[go: up one dir, main page]

PL324091A1 - Compositions and procedure for treating sclerosis multiplex - Google Patents

Compositions and procedure for treating sclerosis multiplex

Info

Publication number
PL324091A1
PL324091A1 PL95324091A PL32409195A PL324091A1 PL 324091 A1 PL324091 A1 PL 324091A1 PL 95324091 A PL95324091 A PL 95324091A PL 32409195 A PL32409195 A PL 32409195A PL 324091 A1 PL324091 A1 PL 324091A1
Authority
PL
Poland
Prior art keywords
compositions
procedure
sclerosis multiplex
treating sclerosis
treating
Prior art date
Application number
PL95324091A
Other languages
English (en)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL324091A1 publication Critical patent/PL324091A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL95324091A 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex PL324091A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15

Publications (1)

Publication Number Publication Date
PL324091A1 true PL324091A1 (en) 1998-05-11

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95324091A PL324091A1 (en) 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex

Country Status (15)

Country Link
EP (1) EP0787147A1 (xx)
JP (1) JPH10504039A (xx)
AU (1) AU4278296A (xx)
BR (1) BR9509438A (xx)
CA (1) CA2203629A1 (xx)
CZ (1) CZ122697A3 (xx)
FI (1) FI971750A (xx)
HU (1) HUT77047A (xx)
IL (1) IL115766A0 (xx)
IS (1) IS4466A (xx)
NO (1) NO971900L (xx)
PL (1) PL324091A1 (xx)
SI (1) SI9520118A (xx)
SK (1) SK51297A3 (xx)
WO (1) WO1996012737A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
DE69739062D1 (de) 1996-03-21 2008-12-04 Circassia Ltd Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CA2330826A1 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
EP1490490B1 (en) 2002-03-27 2009-05-13 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOID DISEASES USING BASIC PROTEINS OF MYELINE OR FRAGMENTS DESCRIBED
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
MX2012004295A (es) 2009-10-12 2012-08-15 Lifebio Lab Llc Composicion para el tratamiento de esclerosis multiple.
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
CN112336851A (zh) 2014-01-13 2021-02-09 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
US12139526B2 (en) 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632991B2 (en) * 1987-06-24 1993-01-21 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU642693B2 (en) * 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
BR9106114A (pt) * 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CA2123228A1 (en) * 1991-11-19 1993-05-27 Bishwajit Nag Mhc subunit conjugates useful in ameliorating deleterious immune responses
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DE69320967T2 (de) * 1992-04-09 1999-05-12 Autoimmune, Inc., Lexington, Mass. Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
JPH08500823A (ja) * 1992-08-17 1996-01-30 オートイミューン インク レトロウィルス関連神経疾患のバイスタンダー抑制
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
HUT74900A (en) * 1994-04-08 1997-02-28 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis

Also Published As

Publication number Publication date
WO1996012737A2 (en) 1996-05-02
NO971900D0 (no) 1997-04-24
CZ122697A3 (en) 1997-09-17
BR9509438A (pt) 1997-12-23
CA2203629A1 (en) 1996-05-02
FI971750A (fi) 1997-06-24
SK51297A3 (en) 1998-03-04
JPH10504039A (ja) 1998-04-14
IS4466A (is) 1997-04-17
EP0787147A1 (en) 1997-08-06
HUT77047A (hu) 1998-03-02
WO1996012737A3 (en) 1996-10-10
SI9520118A (sl) 1998-08-31
IL115766A0 (en) 1996-01-19
FI971750A0 (fi) 1997-04-24
NO971900L (no) 1997-06-25
AU4278296A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
GB9422571D0 (en) Haemorrihoidal compositions and method of use
IL129138A0 (en) Methods and compositions for immunomodulation
IL127446A0 (en) Compositions and methods for coating medical devices
EP0874828A4 (en) PAIN TREATMENT COMPOSITIONS
GB9415421D0 (en) Cosmetic compositions and processes for manufacture thereof
EP0703282A3 (en) Surface treatment composition
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
ZA9510792B (en) Polymerization compounds and compositions
GB9624501D0 (en) Insecticial compositions and method
IL111554A (en) Methods and compositions for hair treatment
GB9405229D0 (en) Compositions of matter
GB9415420D0 (en) Cosmetic compositions and processes for manufacture thereof
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
EP0835092A4 (en) COMPOSITION AND TREATMENT FOR THE CONTROL OF Baldness
HU9701150D0 (en) Composition for preventing and treating disturbances of vision
IL124419A0 (en) Composition for treating pain
GB9508546D0 (en) Method and composition
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
IL113444A0 (en) Compositions and methods for treating leukemia
GB9416340D0 (en) Oil treatment and compositions therefor
ZA953730B (en) Compositions and treatment for multiple sclerosis
ZA959033B (en) Composition and treatment for multiple sclerosis